‹ News

WATT NVTS ATMV NRXS YPF HPK EGY NRGU EVLV HIMS

HIMS: Bullish Engulfing detected on 12 Mar 2026

Overall Score

79 of 100

Good

Win Probability

73%

High

Reward / Risk

2.9 : 1

$0.81 reward $-0.28 risk

Summary Context Technical Indicators

Current Setup

HIMS is forming a bullish engulfing pattern following a 41% surge on March 9 after announcing a Novo Nordisk partnership, currently trading at $25.88. The pattern emerges from an 11-day post-collapse recovery with a breakout score of 13.0, indicating strong directional conviction. Structure score of 11.25 and volume score of 4.8 reflect moderate technical foundation. RSI at 67.6 shows strength approaching overbought levels. The setup sits 88% above its 52-week low ($13.74) but still 63% below the 52-week peak, suggesting room for continuation if the pattern holds.

Stock Context

HIMS announced a strategic collaboration with Novo Nordisk involving GLP-1 weight-loss treatments on March 9, 2026. The agreement brings Ozempic and Wegovy to the platform later this month. This deal removes a major overhang by ending a potential expensive lawsuit that had pressured the stock earlier. Full-year 2025 revenue reached $2.35 billion (59% YoY growth) with 2.5 million subscribers. Needham and Citi upgraded HIMS following the partnership announcement. Barclays raised price target to $29, removing legal uncertainties. The timing aligns with explosive growth in the GLP-1 market—a tailwind justifying the sharp rally.

What to Expect

Full-year 2026 guidance projects revenue of $2.7B to $2.9B with Adjusted EBITDA of $300M to $375M. The conservative target of $27.63 is just 0.65% above current resistance at $27.54, suggesting a tight first breakout level. With win_probability at 73.41%, historical data shows favorable breakout odds. Volume at 111.8M (2.44x average) confirms strong participation. Invalidation occurs below key support at $13.74. A sustained breakout above $27.54 on the elevated volume would validate the pattern, targeting $27.63 initially with potential extension toward consensus analyst price targets around $29-30.

Risk Factors

Concerns include slower adoption of personalized treatments, heightened competition in digital health, and potential regulatory impact. The stock is up over 100% YTD but down over 20% since late July, highlighting growth concerns. High beta of 1.95 amplifies volatility swings; 20-day volatility at 111.78% confirms elevated risk. Next earnings report due May 11, 2026—near-term catalyst risk. Stock susceptible to short squeeze that could crash when squeeze ends. RSI at 67.6 approaches overbought territory, flagging pullback risk. Analyst consensus remains Hold despite the Novo deal, suggesting skepticism persists on fundamentals.

Market & Sector Regime

Market

Neutral -0.18

-1.0 0 +1.0

Health Care Sector

Neutral -0.18

-1.0 0 +1.0

Other Patterns Detected Today

Post Collapse Recovery

11 days in pattern

Moderate 28.0

Overall Score

29 of 40

Good

Pattern Quality

20 of 20

Exceptional

Setup

17 of 20

Strong

R/R

13 of 18

Good

Context

Pattern Quality Score

11 of 15

Good

Structure

13 of 13

Exceptional

Breakout

5 of 12

Weak

Volume

Recent Performance

+57.3%

+63.6%

+33.9%

-33.8%

Momentum & Trend

RSI (14)

67.6

Neutral

MACD Histogram

+1.44

Strong Bullish

Bollinger Band Position

123.0%

Upper Band

Volatility & Risk

20-Day Volatility

1.12

Very High

ATR %

8.5%

High

Beta

1.95

High Beta

Volume Analysis

Volume Ratio

2.44x

Very High

20-Day Avg Vol

45.7M

shares / day

Current Volume

111.8M

shares traded

Price Levels

52W High

$70.42

Target

$27.63

Resistance

$27.54

Current

$25.88

Stop Loss

$23.52

Support

$13.74

52W Low

$13.74

Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.